- Home
- KALV vs VERI Comparison
KALV vs VERI Comparison
Compare KALV & VERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALV | VERI |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.2M | 537.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | KALV | VERI |
|---|---|---|
| Price | $16.12 | $3.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $30.00 | $10.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,426,000.00 | ★ $98,027,000.00 |
| Revenue This Year | N/A | $20.56 |
| Revenue Next Year | $204.16 | $19.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.74 |
| 52 Week Low | $8.74 | $1.22 |
| 52 Week High | $19.00 | $9.42 |
Technical Indicators
Market Signals| Indicator | KALV | VERI |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 31.85 |
| Support Level | $15.22 | $3.46 |
| Resistance Level | $16.16 | $4.25 |
| Average True Range (ATR) | 0.88 | 0.25 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 76.95 | 14.56 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.